Characteristics | FSWs (N = 47) | Non-FSWs (N = 48) | P-value | ||
---|---|---|---|---|---|
n | (%) | n | (%) | ||
Socio-demographic characteristics | |||||
Age, median (IQR), years | 31 | (27, 35) | 35 | (31, 41) | 0.01 |
Education (n = 89) | 0.86 | ||||
Secondary | 10 | (22) | 11 | (26) | |
Primary | 15 | (32) | 12 | (28) | |
Illiterate | 21 | (46) | 20 | (46) | |
Age at first sex, median (IQR), years (n = 89) | 16 | (15, 17) | 16 | (15, 18) | 0.98 |
Married (n = 89) | 10 | (22) | 10 | (23) | 0.86 |
Trip outside the city last 12 months (n = 89) | 24 | (52) | 20 | (47) | 0.59 |
Behavioural characteristics | |||||
Alcohol use in the last week | 30 | (64) | 16 | (33) | 0.003 |
Has a steady sexual partner at enrolment (n = 88) | 37 | (80) | 21 | (50) | 0.003 |
No. sexual intercourses in the last week, median (IQR), (n = 88) | 2 | (0-3) | 0 | (0-1) | < 0.001 |
Always uses condoms with unknown casual sexual partners (n = 88) | 35 | (76) | 31 | (74) | 0.81 |
Always uses condoms with known sexual partners (n = 88) | 25 | (54) | 30 | (71) | 0.10 |
Always uses condoms with steady sexual partner(s) (n = 31) | 3 | (13) | 3 | (38) | 0.16 |
Clinical and biological characteristics | |||||
Body mass index, median (IQR), kg/m2 | 20.7 | (18.4, 23.6) | 19.0 | (17.4, 21.8) | 0.08 |
WHO clinical stages (n = 88)* | 0.94 | ||||
Stage I | 4 | (8) | 4 | (9) | |
Stage II | 10 | (22) | 9 | (22) | |
Stage III | 27 | (59) | 22 | (52) | |
Stage IV | 5 | (11) | 7 | (17) | |
CD4+ count, median (IQR), cells/μL (n = 95) | 147 | (79, 183) | 144 | (100, 197) | 0.12 |
Plasma HIV-1 RNA, mean (95% CI), log10 copies/ml (n = 92) | 4.94 | (4.70, 5.18) | 5.15 | (4.97, 5.33) | 0.16 |
HSV-2 seropositive | 44 | (94) | 46 | (96) | 0.68 |
HAART regimen | 0.11 | ||||
AZT/3TC/efavirenz | 29 | (62) | 24 | (50) | |
d4T/3TC/nevirapine | 10 | (22) | 12 | (25) | |
d4T/3TC/efavirenz | 3 | (6) | 10 | (21) | |
AZT/3TC/nevirapine | 3 | (6) | 1 | (2) | |
AZT/3TC/nelfinavir | 2 | (4) | 0 | (0) | |
AZT/3TC/indinavir-ritonavir | 0 | (0) | 1 | (2) |